Top-Rated Stocks NASDAQ:GH Guardant Health Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Guardant Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $42.26 -2.15 (-4.84%) (As of 06/28/2022 04:00 PM ET) Add Compare Share Today's Range$41.82▼$44.8950-Day Range$28.82▼$69.9552-Week Range$27.65▼$133.82Volume947,724 shsAverage Volume1.33 million shsMarket Capitalization$4.31 billionP/E RatioN/ADividend YieldN/APrice Target$126.90 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter. Email Address GH Stock Forecast (MarketRank)Overall MarketRank™2.09 out of 5 starsMedical Sector493rd out of 1,436 stocksMedical Laboratories Industry15th out of 32 stocksAnalyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 3.5 Analyst's Opinion Consensus RatingGuardant Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $126.90, Guardant Health has a forecasted upside of 200.3% from its current price of $42.26.Amount of Analyst CoverageGuardant Health has only been the subject of 1 research reports in the past 90 days. Previous Next 4.7 Community Rank Outperform VotesGuardant Health has received 230 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGuardant Health has received 99 “underperform” votes. (Add your “underperform” vote.)Community SentimentGuardant Health has received 69.91% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Guardant Health and other stocks. Vote “Outperform” if you believe GH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGuardant Health does not currently pay a dividend.Dividend GrowthGuardant Health does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Guardant Health insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.80% of the stock of Guardant Health is held by insiders.Percentage Held by Institutions93.69% of the stock of Guardant Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Guardant Health are expected to grow in the coming year, from ($4.75) to ($4.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Guardant Health is -10.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Guardant Health is -10.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGuardant Health has a P/B Ratio of 6.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Guardant Health (NASDAQ:GH)Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.Read More GH Stock News HeadlinesJune 20, 2022 | seekingalpha.comGuardant Health (GH) Presents at the William Blair 42nd Annual Growth Stock Conference - SlideshowJune 5, 2022 | americanbankingnews.comGuardant Health (NASDAQ:GH) Trading Down 6.6%June 4, 2022 | americanbankingnews.comPiper Sandler Initiates Coverage on Guardant Health (NASDAQ:GH)June 2, 2022 | finance.yahoo.comWhy Shares of Guardant Health Dropped 33.6% in MayMay 26, 2022 | finanznachrichten.deGuardant Health, Inc.: First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d'Hebron Institute of OncologyMay 21, 2022 | finance.yahoo.comGuardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022May 6, 2022 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Guardant HealthMay 6, 2022 | seekingalpha.comGuardant Health hits 52-week low after 1Q earningsMay 6, 2022 | finance.yahoo.comWhy Guardant Health Stock Is Crashing TodayMay 4, 2022 | seekingalpha.comGuardant Health Q1 2022 Earnings PreviewMay 3, 2022 | barrons.comGuardant Launches a Blood Screen for Cancer, in Challenge to Illumina and Exact SciencesApril 28, 2022 | finance.yahoo.comEarnings Preview: Guardant Health (GH) Q1 Earnings Expected to DeclineApril 28, 2022 | finance.yahoo.comThis Chart Is Why I'm Not Worried About Guardant HealthSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GH CUSIPN/A CIK1576280 Webwww.guardanthealth.com Phone(855) 698-8887Fax888-974-4258Employees1,373Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today6/28/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$126.90 High Stock Price Forecast$165.00 Low Stock Price Forecast$65.00 Forecasted Upside/Downside+200.3%Consensus RatingBuy Rating Score (0-4)3 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($4.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-405.67 million Net Margins-107.20% Pretax Margin-102.40% Return on Equity-62.68% Return on Assets-18.94% Debt Debt-to-Equity Ratio2.13 Current Ratio4.87 Quick Ratio4.71 Sales & Book Value Annual Sales$373.65 million Price / Sales11.53 Cash FlowN/A Price / Cash FlowN/A Book Value$6.34 per share Price / Book6.67Miscellaneous Outstanding Shares101,923,000Free Float96,011,000Market Cap$4.31 billion OptionableNot Optionable Beta0.73 Guardant Health Frequently Asked Questions Should I buy or sell Guardant Health stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Guardant Health stock. View analyst ratings for Guardant Health or view top-rated stocks. What is Guardant Health's stock price forecast for 2022? 10 analysts have issued twelve-month price targets for Guardant Health's stock. Their GH stock forecasts range from $65.00 to $165.00. On average, they anticipate Guardant Health's share price to reach $126.90 in the next year. This suggests a possible upside of 200.3% from the stock's current price. View analysts' price targets for Guardant Health or view top-rated stocks among Wall Street analysts. How has Guardant Health's stock performed in 2022? Guardant Health's stock was trading at $100.02 at the beginning of the year. Since then, GH stock has decreased by 57.7% and is now trading at $42.26. View the best growth stocks for 2022 here. When is Guardant Health's next earnings date? Guardant Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Guardant Health. How were Guardant Health's earnings last quarter? Guardant Health, Inc. (NASDAQ:GH) released its earnings results on Thursday, May, 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.23) by $0.02. The business earned $96.10 million during the quarter, compared to the consensus estimate of $95.71 million. Guardant Health had a negative trailing twelve-month return on equity of 62.68% and a negative net margin of 107.20%. Guardant Health's quarterly revenue was up 22.2% compared to the same quarter last year. During the same period last year, the business earned ($1.06) earnings per share. View Guardant Health's earnings history. What guidance has Guardant Health issued on next quarter's earnings? Guardant Health issued an update on its FY 2022 earnings guidance on Monday, May, 30th. The company provided EPS guidance of for the period. The company issued revenue guidance of $460.00 million-$470.00 million, compared to the consensus revenue estimate of $465.93 million. Who are Guardant Health's key executives? Guardant Health's management team includes the following people: Dr. Helmy Eltoukhy Ph.D., Co-Founder, Co-CEO & Chairman (Age 43, Pay $13.66k)Dr. AmirAli Talasaz Ph.D., Co-CEO & Director (Age 42, Pay $13.27k)Mr. Michael Bell, Chief Financial Officer (Age 53, Pay $1.2M)Mr. John G. Saia, Chief Legal Officer (Age 49, Pay $641.22k)Dr. Craig Eagle M.D., Chief Medical Officer (Age 55, Pay $2.88M)Mr. Christopher Freeman, Chief Commercial Officer of Oncology Bus. (Age 48, Pay $740.23k)Mr. Andy Ament, Sr. VP of OperationsDarya Chudova, Sr. VP of TechnologyMr. Kumud Kalia, Chief Information OfficerMs. Jennifer Higgins, VP of Public Affairs What is Helmy Eltoukhy's approval rating as Guardant Health's CEO? 52 employees have rated Guardant Health CEO Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among Guardant Health's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Guardant Health's key competitors? Some companies that are related to Guardant Health include Quest Diagnostics (DGX), Exact Sciences (EXAS), Natera (NTRA), Elekta AB (publ) (EKTAY), Fulgent Genetics (FLGT), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Invitae (NVTA), Viridian Therapeutics (VRDN), Burning Rock Biotech (BNR), Personalis (PSNL), DermTech (DMTK) and Renalytix (RNLX). View all of GH's competitors. What other stocks do shareholders of Guardant Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Square (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO). When did Guardant Health IPO? (GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers. What is Guardant Health's stock symbol? Guardant Health trades on the NASDAQ under the ticker symbol "GH." Who are Guardant Health's major shareholders? Guardant Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.59%), Capital International Investors (4.99%), Capital Research Global Investors (3.93%), Clearbridge Investments LLC (3.29%), Goldman Sachs Group Inc. (1.66%) and Massachusetts Financial Services Co. MA (1.18%). Company insiders that own Guardant Health stock include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Michael J Wiley, Richard B Lanman, Samir Kaul, Stanley J Meresman, Stanley J Meresman, Timothy P Eckersley and Vision Fund (Aiv M1) Softbank. View institutional ownership trends for Guardant Health. Which major investors are selling Guardant Health stock? GH stock was sold by a variety of institutional investors in the last quarter, including Nicholas Investment Partners LP, Capital Research Global Investors, Russell Investments Group Ltd., Zurcher Kantonalbank Zurich Cantonalbank , Chevy Chase Trust Holdings Inc., Group One Trading L.P., RTW Investments LP, and LA Financiere DE L Echiquier. Company insiders that have sold Guardant Health company stock in the last two years include Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Samir Kaul, and Stanley J Meresman. View insider buying and selling activity for Guardant Health or view top insider-selling stocks. Which major investors are buying Guardant Health stock? GH stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, Steadfast Capital Management LP, RA Capital Management L.P., Alyeska Investment Group L.P., Ensign Peak Advisors Inc, Blue Water Life Science Advisors LP, Clearbridge Investments LLC, and Artemis Investment Management LLP. View insider buying and selling activity for Guardant Health or or view top insider-buying stocks. How do I buy shares of Guardant Health? Shares of GH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Guardant Health's stock price today? One share of GH stock can currently be purchased for approximately $42.26. How much money does Guardant Health make? Guardant Health (NASDAQ:GH) has a market capitalization of $4.31 billion and generates $373.65 million in revenue each year. The company earns $-405.67 million in net income (profit) each year or ($4.12) on an earnings per share basis. How many employees does Guardant Health have? Guardant Health employs 1,373 workers across the globe. How can I contact Guardant Health? Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for Guardant Health is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at [email protected], or via fax at 888-974-4258. This page (NASDAQ:GH) was last updated on 6/28/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here